

Endo - Recall of clonazepam orally disintegrating tablets

- On July 5, 2024, <u>Endo announced</u> a consumer level recall of one lot of <u>clonazepam</u> orally disintegrating 0.25 mg tablets because they may have been packaged in a carton labelled as 0.125 mg.
- Endo shipped the recalled lot from April 2024 to June 2024.

Product Description	NDC number	Lot number (Exp Date)
Clonazepam orally disintegrating tablets, 0.25 mg	49884-307-02	550147301 (Aug 2026)

- Clonazepam orally disintegrating tablet is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam orally disintegrating tablets may be useful. Clonazepam is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V.
- Anyone with the affected lot on hand should stop distribution and return product. Patients should contact their healthcare provider with any medical related questions.
- Contact Inmar (appointed company for Endo) by phone at 1-877-890-0765 for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.